| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Loss on disposal of property and equipment | NaN | 0 | 0 | -103 |
| Net loss | -20,244 | -30,516 | -26,856 | -59,431 |
| Depreciation and amortization expense | 1,342 | 1,473 | 1,573 | 3,335 |
| Noncash lease expense | 743 | 1,028 | 682 | 1,673 |
| Stock-based compensation expense | 1,303 | 5,650 | 2,529 | 6,088 |
| Net amortization of premiums and accretion discounts on investments | 790 | 1,212 | 705 | 2,176 |
| Amortization of deferred transaction costs | 0 | 28 | 0 | 15 |
| Prepaid expenses and other current assets | 85 | -1,191 | 619 | -1,109 |
| Other non-current assets | -3 | -4 | -116 | -188 |
| Accounts payable | -1,800 | 307 | 1,213 | -491 |
| Operating lease liability | -817 | -796 | -778 | -1,875 |
| Accrued and other current and non-current liabilities | -1,145 | 1,934 | 538 | -568 |
| Net cash used in operating activities | -21,490 | -20,909 | -22,307 | -52,030 |
| Purchases of short-term treasury securities | 20,084 | 79,545 | 26,955 | 34,369 |
| Maturities of short term treasury securities | -39,000 | -35,000 | -44,000 | -66,000 |
| Purchases of property and equipment | 37 | -10 | 209 | 1,539 |
| Net cash provided by (used in) investing activities | 18,879 | -44,535 | 16,836 | 30,092 |
| Proceeds from issuance of common stock pursuant to at-the-market offering, net of issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock and pre-funded warrants pursuant to underwritten public offering, net of issuance costs | NaN | 75,172 | 0 | 0 |
| Proceeds from exercise of stock options | NaN | 1 | 0 | 0 |
| Proceeds from employee stock purchase plan | NaN | 59 | 0 | 267 |
| Taxes withheld and paid related to net share settlement of equity awards | -65 | 0 | 0 | -104 |
| Principal payments on finance leases | NaN | 0 | 150 | NaN |
| Net cash used in financing activities | -65 | 75,232 | -150 | 163 |
| Net change in cash, cash equivalents and restricted cash | -2,676 | 9,788 | -5,621 | -21,775 |
| Cash, cash equivalents and restricted cash at the beginning of period | 41,790 | 32,002 | 59,398 | NaN |
| Cash, cash equivalents and restricted cash at the end of period | 39,114 | 41,790 | 32,002 | NaN |
Adicet Bio, Inc. (ACET)
Adicet Bio, Inc. (ACET)